HWM
ACAD icon

Hohimer Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Hohimer Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.32M Hold
91,800
– – 0.23% 126
2026
Q1 		$2.04M Sell
91,800
-10,000
-10% -$239K 0.24% 127
2025
Q4 		$2.72M Hold
101,800
– – 0.37% 86
2025
Q3 		$2.17M Sell
101,800
-16,083
-14% -$380K 0.3% 106
2025
Q2 		$2.54M Sell
117,883
-42,759
-27% -$795K 0.45% 72
2025
Q1 		$2.67M Sell
160,642
-913
-0.6% -$16.6K 0.52% 68
2024
Q4 		$2.96M Buy
161,555
+2,422
+2% +$39.1K 0.56% 65
2024
Q3 		$2.45M Hold
159,133
– – 0.53% 78
2024
Q2 		$2.59M Buy
159,133
+142,000
+829% +$2.29M 0.6% 71
2024
Q1 		$317K Hold
17,133
– – 0.07% 197
2023
Q4 		$536K Hold
17,133
– – 0.14% 150
2023
Q3 		$357K Sell
17,133
-750
-4% -$20.4K 0.1% 160
2023
Q2 		$428K Sell
17,883
-2,382
-12% -$52.9K 0.12% 153
2023
Q1 		$381K Hold
20,265
– – 0.11% 157
2022
Q4 		$323K Buy
20,265
+4,250
+27% +$66.4K 0.1% 135
2022
Q3 		$262K Sell
16,015
-500
-3% -$8.1K 0.08% 153
2022
Q2 		$233K Hold
16,515
– – 0.07% 166
2022
Q1 		$400K Hold
16,515
– – 0.08% 156
2021
Q4 		$385K Hold
16,515
– – 0.08% 153
2021
Q3 		$274K Buy
16,515
+1,980
+14% +$38.2K 0.06% 157
2021
Q2 		$355K Buy
+14,535
New +$328K 0.07% 155
2021
Q1 		– Sell
-3,865
Closed -$207K – 200
2020
Q4 		$207K Buy
+3,865
New +$192K 0.05% 174
2020
Q3 		– Sell
-6,365
Closed -$309K – 181
2020
Q2 		$309K Buy
6,365
+2,500
+65% +$120K 0.11% 161
2020
Q1 		$201K Sell
3,865
-9,000
-70% -$371K 0.08% 170
2019
Q4 		$550K Buy
+12,865
New +$560K 0.19% 162

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hohimer Wealth Management's ACAD Position: Q2 2026 in Review

Hohimer Wealth Management held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 91,800 shares worth $2.32M. The position accounts for 0.23% of the portfolio, ranked #126.

Hohimer Wealth Management first reported a position in ACAD in Q4 2019 and has held it in 25 quarters since. The position peaked at $2.96M in Q4 2024. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Hohimer Wealth Management held 91,800 shares of Acadia Pharmaceuticals worth $2.32M as of Q2 2026.
  • Hohimer Wealth Management left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up 0.23% of Hohimer Wealth Management's portfolio in Q2 2026, its #126 holding.
  • Hohimer Wealth Management first reported a position in Acadia Pharmaceuticals in Q4 2019 and has held it in 25 quarters since.
  • Hohimer Wealth Management's Acadia Pharmaceuticals position peaked at $2.96M in Q4 2024.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Hohimer Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.